Neonatal clinical pharmacology

Paediatric Anaesthesia

Volumn 24, Issue 1, 2014, Pages 30-38

  Allegaert, Karel ^a,b   Van De Velde, Marc ^a,b   Van Den Anker, John ^c,d,e  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

anesthesia; infant; newborn; ontogeny; pharmacodynamics; pharmacokinetics

Indexed keywords

BUPIVACAINE; CEFAZOLIN; CODEINE; DISINFECTANT AGENT; EMLA; INHALATION ANESTHETIC AGENT; MIDAZOLAM; NEUROMUSCULAR BLOCKING AGENT; PARACETAMOL; PROPOFOL;

CLINICAL PHARMACOLOGY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SURVEILLANCE PROGRAM; HUMAN; MATURATION; NEWBORN; NEWBORN CARE; PHARMACEUTICAL CARE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

ANESTHESIA; INFANT; NEWBORN; ONTOGENY; PHARMACODYNAMICS; PHARMACOKINETICS;

BODY WEIGHT; HUMANS; INFANT, NEWBORN; KIDNEY; LIVER; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL;

EID: 84890618295     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/pan.12176     Document Type: Review

References (51)

1. Anderson BJ, Allegaert K,. The pharmacology of anaesthetics in the neonate. Best Pract Res Clin Anaesthesiol 2010; 24: 419-431.
2. Smits A, Kulo A, de Hoon JN, et al,. Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations. Curr Pharm Des 2012; 18: 3119-3146.
3. Anderson BJ,. Pharmacology in the very young: anaesthetic implications. Eur J Anaesthesiol 2012; 29: 261-270.
4. Sumpter A, Anderson BJ,. Pediatric pharmacology in the first year of life. Curr Opin Anaesthesiol 2009; 22: 469-475.
5. Allegaert K, Verbesselt R, Naulaers G, et al,. Developmental pharmacology: neonates are not just small adults. Acta Clin Belg 2008; 63: 16-24.
6. Anderson BJ, Holford NH,. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25-36.
7. van den Anker JN,. Developmental pharmacology. Dev Disabil Res Rev 2010; 16: 233-238.
8. de Wildt SN,. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol 2011; 7: 935-948.
9. Coté CJ, Ward RM, Lugo RA, et al,. Pharmacokinetics and pharmacology of drugs used in children (section II, chapter 6). In:, Coté CJ, Lerman J, Todres ID, eds. A Practice of Anesthesia for Infants and Children, 4th edn. Philadelphia, PA: Saunders Elsevier, 2009: 89-146.
10. Hines RN,. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm doi 10.1016/j.ijpharm.2012.05.079.
11. Davidson AJ,. Anesthesia and neurotoxicity to the developing brain: the clinical relevance. Pediatr Anesth 2011; 21: 716-721.
12. Shinwell ES, Eventov-Friedman S,. Impact of perinatal corticosteroids on neuromotor development and outcome: review of the literature and new meta-analysis. Semin Fetal Neonatal Med 2009; 14: 164-170.
13. Zaffanello M, Bassareo PP, Cataldi L, et al,. Long-term effects of neonatal drugs on the kidney. J Matern Fetal Neonatal Med 2010; 23 (Suppl 3): 87-89.
14. Yilmaz D, Teziç HT, Zorlu P, et al,. Single dose povidone-iodine on thyroid functions and urinary iodine excretion. Indian J Pediatr 2003; 70: 675-677.
15. Smits A, Kulo A, Verbesselt R, et al,. Cefazolin plasma protein binding and its covariates in neonates. Eur J Clin Microbiol Infect Dis 2012; 31: 3359-3365.
16. Calder A, Bell GT, Andersson M, et al,. Pharmacokinetic profiles of epidural bupivacaine and ropivacaine following single-shot and continuous epidural use in young infants. Pediatr Anesth 2012; 22: 430-437.
17. Allegaert K, de Hoon J, Verbesselt R, et al,. Maturational pharmacokinetics of single intravenous bolus of propofol. Pediatr Anesth 2007; 17: 1028-1034.
18. Smits A, Verbesselt R, Kulo A, et al,. Urinary metabolites after intravenous propofol bolus in neonates. Eur J Drug Metab Pharmacokinet doi: 10.1007/s13318-012-0109-6.
19. Welzing L, Kribs A, Eifinger F, et al,. Propofol as an induction agent for endotracheal intubation can cause significant arterial hypotension in preterm neonates. Pediatr Anesth 2010; 20: 605-611.
20. Allegaert K, Palmer GM, Anderson BJ,. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Arch Dis Child 2011; 96: 575-580.
21. Anderson BJ, Allegaert K,. Intravenous neonatal paracetamol dosing: the magic of 10 days. Pediatr Anesth 2009; 19: 289-295.
22. Anderson BJ, Larsson P,. A maturation model for midazolam clearance. Pediatr Anesth 2011; 21: 302-308.
23. Larson A, Stidman T, Banerji S, et al,. Seizures and methemoglobinemia in an infant after excessive EMLA application. Pediatr Emerg Care 2013; 29: 377-379.
24. Sistonen J, Madadi P, Ross CJ, et al,. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther 2012; 91: 692-699.
25. Holford NH, Ma SC, Anderson BJ,. Prediction of morphine dose in humans. Pediatr Anesth 2012; 22: 209-222.
26. Anderson BJ, van Lingen RA, Hansen TG, et al,. Acetaminophen developmental pharmacokinetics in premature neonates and infants. Anesthesiology 2002; 96: 1336-1345.
27. Anderson BJ, Pons G, Autret-Leca E, et al,. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Pediatr Anesth 2005; 15: 282-292.
28. Allegaert K, Rayyan M, De Rijdt T, et al,. Hepatic tolerance of repeated intravenous paracetamol administration in neonates. Pediatr Anesth 2008; 18: 388-392.
29. Anderson BJ,. Paracetamol (acetaminophen): mechanisms of action. Pediatr Anesth 2008; 18: 915-921.
30. Allegaert K, Naulaers G, Vanhaesebrouck S, et al,. The paracetamol concentration-effect relation in neonates. Pediatr Anesth 2013; 23: 45-50.
31. Anderson BJ, Woollard GA, Holford NH,. Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. Eur J Clin Pharmacol 2001; 57: 559-569.
32. Ceelie I, de Wildt SN, van Dijk M, et al,. Effect of intravenous paracetamol on postoperative morphine requirements in neonates and infants undergoing major noncardiac surgery: a randomized controlled trial. JAMA 2013; 309: 149-154.
33. Shaheen SO, Newson RB, Ring SM, et al,. Prenatal and infant acetaminophen exposure, antioxidant gene polymorphisms, and childhood asthma. J Allergy Clin Immunol 2010; 126: 1141-1148. e7
34. Lowe AJ, Carlin JB, Bennett CM, et al,. Paracetamol use in early life and asthma: prospective birth cohort study. BMJ 2010; 341: c4616.
35. Oncel MY, Yurttutan S, Degirmencioglu H, et al,. Intravenous paracetamol treatment in the management of patent ductus arteriosus in Extremely Low Birth Weight Infants. Neonatology 2012; 103: 165-168.
36. Hammerman C, Bin-Nun A, Kaplan M,. Managing the patent ductus arteriosus in the premature neonate: a new look at what we thought we knew. Semin Perinatol 2012; 36: 130-138.
37. Anderson BJ,. My child is unique; the pharmacokinetics are universal. Pediatr Anesth 2012; 22: 530-538.
38. Sneyd JR, Simons PJ, Wright B,. Use of proton nmr spectroscopy to measure propofol metabolites in the urine of the female Caucasian patient. Xenobiotica 1994; 24: 1021-1028.
39. Allegaert K, Peeters MY, Verbesselt R, et al,. Interindividual variability in propofol pharmacokinetics in preterm and term neonates. Br J Anaesth 2007; 99: 864-870.
40. Hannam JA, Anderson BJ,. Contribution of morphine and morphine-6-glucuronide to respiratory depression in a child. Anaesth Intensive Care 2012; 40: 867-870.
41. Allegaert K, van den Anker JN, de Hoon JN, et al,. Covariates of tramadol disposition in the first months of life. Br J Anaesth 2008; 100: 525-532.
42. Allegaert K, Rochette A, Veyckemans F,. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Pediatr Anesth 2011; 21: 266-273.
43. Leeder JS, Kearns GL,. Intepreting pharmacogenetic data in the developing neonate: the challenge of hitting a moving target. Clin Pharmacol Ther 2012; 92: 434-436.
44. Zhu R, Kiser JJ, Seifart HI, et al,. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol 2012; 52: 511-519.
45. Strougo A, Eissing T, Yassen A, et al,. First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. J Pharmacokinet Pharmacodyn 2012; 39: 195-203.
46. Johnson TN, Rostami-Hodjegan A,. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Pediatr Anesth 2011; 21: 291-301.
47. De Cock RF, Piana C, Krekels EH, et al,. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 2011; 67: 5-16.
48. Choonara I,. Educational Paper: aspects of clinical pharmacology in children-pharmacovigilance and safety. Eur J Pediatr doi: 10.1007/s00431-012- 1871-9.
49. Hallett BR, Chalkiadis GA,. Suspected opioid-induced hyperalgesia in an infant. Br J Anaesth 2012; 108: 116-118.
50. Madden K, Turkel S, Jacobson J, et al,. Recurrent delirium after surgery for congenital heart disease in an infant. Pediatr Crit Care Med 2011; 12: e413-e415.
51. Sammartino M, Garra R, Sbaraglia F, et al,. Propofol overdose in a preterm baby: may propofol infusion syndrome arise in two hours? Pediatr Anesth 2010; 20: 973-974.